Private equity firm the Carlyle Group (Nasdaq: CG) has formed a new pharmaceutical company in partnershhip with health care focused investment bank and consulting firm Bourne Partners.

The new platform, known as Phoenix Therapeutics, will be majority owned by Carlyle with Bourne taking a minority stake. Phoenix will look for acquisitions in the pharmaceutical space.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.